Prestige Consumer Healthcare In found using ticker (PBH) now have 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 75 and 63 with the average target price sitting at 68.75. Now with the previous closing price of 55.23 this would indicate that there is a potential upside of 24.5%. The day 50 moving average is 56.11 and the 200 day MA is 57.16. The market capitalisation for the company is $2,750m. Find out more information at: https://www.prestigebrands.com
The potential market cap would be $3,424m based on the market concensus.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody’s analgesic powders, Boudreaux’s Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden’s cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer’s Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
